Ignite Creation Date:
2025-12-25 @ 12:38 AM
Ignite Modification Date:
2026-02-04 @ 8:28 PM
Study NCT ID:
NCT02573467
Status:
COMPLETED
Last Update Posted:
2018-03-13
First Post:
2015-07-09
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-11-02
Start Date Type:
ACTUAL
Primary Completion Date:
2016-08-17
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-02-13
Completion Date Type:
ACTUAL
First Submit Date:
2015-07-09
First Submit QC Date:
None
Study First Post Date:
2015-10-09
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-02-12
Results First Submit QC Date:
None
Results First Post Date:
2018-03-13
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-02-12
Last Update Post Date:
2018-03-13
Last Update Post Date Type:
ACTUAL